Peter Olupot-Olupot/Lancet Haematol
Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.Aygun B
Lane A
Smart LR
Santos B
Tshilolo L
Williams TN
Olupot-Olupot P
Stuber SE
Tomlinson G
Latham T
Ware RE
Reach Investigators
Lancet Haematol, (2024). 11:e425-e435
